PYC Therapeutics (PYC) investor relations material

Executive summary

• Precision RNA therapies are being developed for genetic diseases with four drug programs, three in clinical development and all with disease-modifying potential.

• Up to A$653 million is being raised via an institutional placement and a 3-for-5 pro-rata accelerated non-renounceable entitlement offer at A$1.50 per share.

• The capital raise will extend the cash runway into CY2030, enabling delivery of clinical efficacy data for all four programs and advancing them into registrational trials.

• The raise allows both specialist life sciences investors and existing shareholders to participate, supporting the transition to a commercial-stage company.

Pipeline and clinical milestones

• Four clinical-stage drug candidates target major unmet needs: Polycystic Kidney Disease, Phelan-McDermid Syndrome, Retinitis Pigmentosa type 11, and Autosomal Dominant Optic Atrophy.

• Human data readouts are expected for all programs between 2026 and 2028, with registrational trial initiations planned.

• Positive data will enable advancement into registrational trials, creating commercial optionality including potential partnerships or launches.

• Each program addresses the root genetic cause of its indication, with up to 5x higher probability of success than industry average.

Market opportunity and company positioning

• Each drug candidate targets diseases with no established standard of care and market sizes between US$1–10 billion per annum.

• The company will have over $750 million in cash post-raise, supporting a diversified late-stage portfolio and near-term human efficacy catalysts.

• Shareholder register will include leading global life science investors.